About This Calculator

This Adcetris (brentuximab vedotin) Dosing Calculator is a supplementary resource designed for healthcare professionals. It helps determine the correct patient-specific dose based on weight and the selected clinical indication, in accordance with the standard dosing regimens. The tool also provides practical information on the number of vials required and potential drug waste to aid in preparation and administration.

Outputs Explained

After entering the required patient data, the calculator provides the following key outputs:

• Final Administered Dose (mg): The total dose to be administered. This value is capped at a maximum of 180 mg per cycle, even if the weight-based calculation exceeds this amount.
• Vials Required: The number of 50 mg single-dose vials needed to prepare the final dose. This is calculated by rounding up to the nearest whole vial.
• Total Drug Reconstituted (mg): The total amount of brentuximab vedotin available after reconstituting the required number of vials (e.g., 3 vials = 150 mg).
• Drug Waste (mg): The amount of reconstituted drug that will be discarded after drawing up the final administered dose.

How to Use the Calculator

To use the tool effectively, please follow these steps:

1. Enter Patient Weight: Input the patient’s current weight in either kilograms (kg) or pounds (lbs). The corresponding unit will be automatically converted and updated.
2. Select Clinical Indication: Choose the appropriate indication from the dropdown menu. This selection determines the dosing regimen (either 1.8 mg/kg or 1.2 mg/kg).
3. Calculate: Click the “Calculate Dose” button to generate the complete dosing summary. The results will appear below the input panel.

Dosing Overview

Adcetris is administered as an intravenous infusion. The dosing is weight-based, subject to a maximum recommended dose.

• Standard Dosing (1.8 mg/kg): This regimen is used for most indications, including previously untreated systemic anaplastic large cell lymphoma (sALCL), relapsed/refractory classical Hodgkin lymphoma (cHL), and as consolidation therapy post-autologous stem cell transplant (ASCT) in cHL patients at high risk. The maximum dose is 180 mg.
• A+AVD Regimen (1.2 mg/kg): This lower dose is used specifically for previously untreated Stage III or IV cHL when Adcetris is given in combination with doxorubicin, vinblastine, and dacarbazine (AVD). The maximum dose is 120 mg per cycle for this regimen.

Dose Capping: For patients weighing more than 100 kg, the dose should be calculated based on a weight of 100 kg, resulting in the maximum dose of 180 mg for the 1.8 mg/kg regimen. This calculator automatically applies this cap.

Switching Between Regimens

Any decision to switch a patient from one treatment regimen to another should be based on a comprehensive clinical evaluation, disease progression, and the most current treatment guidelines. This tool is not designed to provide guidance on treatment selection or regimen changes. Always refer to the full prescribing information and institutional protocols.

Missed Dose Information

If a planned dose of Adcetris is missed, it should be administered as soon as possible. The subsequent dosing schedule should be adjusted accordingly to maintain the intended treatment interval. Patients should not wait until the next scheduled dose. Clinical judgment is required, and consultation of the prescribing information is recommended for specific guidance.

Important Safety Considerations

This calculator does not account for necessary dose modifications due to adverse reactions or organ impairment. Key safety considerations from the prescribing information include:

• Peripheral Neuropathy: A very common adverse reaction that may require dose modification or discontinuation.
• Hepatic and Renal Impairment: Dose adjustments are recommended for patients with moderate to severe hepatic impairment or severe renal impairment.
• Infusion-Related Reactions: Anaphylaxis and other infusion-related reactions can occur. Patients should be monitored during infusion.
• Progressive Multifocal Leukoencephalopathy (PML): Cases of PML have been reported in patients receiving Adcetris.

This is not a complete list of risks. Always consult the full official prescribing information before administration.

Frequently Asked Questions

Why is the final dose capped at 180 mg?

The maximum recommended dose of Adcetris is 180 mg per infusion (for the 1.8 mg/kg regimen) based on clinical trial data. This cap is a safety measure to manage toxicity, especially for patients weighing over 100 kg. The calculator automatically enforces this limit.

How does the calculator determine the number of vials?

Adcetris is supplied in 50 mg single-dose vials. The calculator divides the final administered dose by 50 and rounds the result up to the nearest whole number to ensure enough drug is available for preparation.

Does this calculator account for dose reductions from toxicity?

No. This tool calculates the initial recommended dose based on weight and indication only. It does not provide recommendations for dose reductions due to adverse events like peripheral neuropathy. Such adjustments must be made based on clinical assessment and the guidance in the prescribing information.

Can I use this calculator for pediatric patients?

The safety and effectiveness of Adcetris have been established in pediatric patients for certain indications. However, this tool is intended as a general guide. Dosing for pediatric patients should be strictly verified against the most current prescribing information and institutional protocols.

What is the reconstituted concentration of Adcetris?

Each 50 mg vial of Adcetris should be reconstituted with 10.5 mL of Sterile Water for Injection, USP, to yield a final concentration of 5 mg/mL. Refer to the prescribing information for full reconstitution and dilution instructions.

Why is it important to select the correct clinical indication?

The selected indication directly determines the dose per kilogram (1.8 mg/kg vs. 1.2 mg/kg). Choosing the wrong indication will result in an incorrect dose calculation, which could impact treatment efficacy and patient safety.

How is drug waste calculated?

Drug waste is the difference between the total amount of drug available after reconstituting all required vials and the final dose administered to the patient. For example, if a 165 mg dose is required, 4 vials (200 mg total) are needed, resulting in 35 mg of waste.

What happens if I enter a patient’s weight in both kg and lbs?

The tool is designed for convenience. If you enter a weight in one unit (e.g., kg), the other unit (lbs) will update automatically. If you then change the second unit, the first one will update in turn. The calculation is always based on the most recently entered or updated weight, converted to kg.

References

• ADCETRIS® (brentuximab vedotin) for injection, for intravenous use. U.S. Prescribing Information. Seagen Inc. Revised: December 2022. Available at: FDA.gov
• Adcetris (brentuximab vedotin) Healthcare Professionals Page. Seagen. Available at: adcetris-hcp.com
• Adcetris (brentuximab vedotin) European public assessment report (EPAR). European Medicines Agency. Available at: ema.europa.eu
• National Cancer Institute (NCI). Brentuximab Vedotin. NCI Drug Dictionary. Available at: cancer.gov